Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study
- 1 June 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (11), 2138-2146
- https://doi.org/10.1200/jco.2003.12.154
Abstract
Purpose: Quality of life (QOL) outcomes in patients with chronic myeloid leukemia (CML) were evaluated in an international phase III study.Keywords
This publication has 38 references indexed in Scilit:
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood, 2002
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood, 2002
- Imatinib Mesylate — A New Oral Targeted TherapyNew England Journal of Medicine, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Chronic myeloid leukemia: current treatment optionsBlood, 2001
- Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2000
- Psychiatric Side Effects of Interferon Therapy: Prevalence, Proposed Mechanisms, and Future DirectionsJournal of Clinical Oncology, 2000
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Chronic myelogenous leukemia: a concise updateBlood, 1993